Nanobiotix (XPAR:NANO) LT-Debt-to-Total-Asset : 0.49 (As of Dec. 2023)

View and export this data going back to 2012. Start your Free Trial

What is Nanobiotix LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Nanobiotix's long-term debt to total assests ratio for the quarter that ended in Dec. 2023 was 0.49.

Nanobiotix's long-term debt to total assets ratio declined from Dec. 2022 (0.81) to Dec. 2023 (0.49). It may suggest that Nanobiotix is progressively becoming less dependent on debt to grow their business.

Nanobiotix LT-Debt-to-Total-Asset Historical Data

The historical data trend for Nanobiotix's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nanobiotix LT-Debt-to-Total-Asset Chart

Nanobiotix Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.77

0.33

0.37

0.81

0.49

Nanobiotix Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.37	0.45	0.81	1.09	0.49

Nanobiotix LT-Debt-to-Total-Asset Calculation

Nanobiotix's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (A: Dec. 2023 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2023 )	/	Total Assets (A: Dec. 2023 )
	=	45.543	/	93.897
	=	0.49

Nanobiotix's Long-Term Debt to Total Asset Ratio for the quarter that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (Q: Dec. 2023 )	=	Long-Term Debt & Capital Lease Obligation (Q: Dec. 2023 )	/	Total Assets (Q: Dec. 2023 )
	=	45.543	/	93.897
	=	0.49

Nanobiotix (XPAR:NANO) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Nanobiotix LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Nanobiotix's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Nanobiotix (XPAR:NANO) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nanobiotix SA (XPAR:NANO) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

NBTX:USA 5NR:Germany

Address

60 Rue de Wattignies, Paris, FRA, 75012

Website

https://www.nanobiotix.com

Nanobiotix SA is a clinical-stage biotechnology company that has one operating segment, which focuses on developing product candidates that use its proprietary nanotechnology to transform cancer treatment by increasing the efficacy of radiotherapy. It develops NanoXray products to help patients receiving radiotherapy by magnifying the effect of radiotherapy within tumor cells without increasing the dose to surrounding healthy tissues. Its product candidate is NBTXR3, a preclinical research program for cancer immunotherapies.

Nanobiotix (XPAR:NANO) Headlines

No Headlines